Tazobactum%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin is a broad-spectrum penicillin antibiotic, and tazobactam is a beta-lactamase inhibitor. This combination extends the spectrum of piperacillin to include many beta-lactamase producing bacteria. It is typically administered intravenously. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin structure infections (including diabetic foot infections) * Community-acquired pneumonia * Nosocomial pneumonia * Bacterial meningitis (when documented or suspected to be caused by susceptible organisms) * Empirical treatment of febrile neutropenia ## Adult Dosing * **Standard Dosing:** 3.375 grams (3g piperacillin/0.375g tazobactam) or 4.5 grams (4g piperacillin/0.5g tazobactam) intravenously every 6 to 8 hours. * **Severe Infections/High Inoculum:** Doses of 4.5 grams every 6 hours may be used. * **Maximum Dose:** Not explicitly defined, but typically limited by tazobactam's capacity to inhibit beta-lactamases and avoid excessive sodium load. Doses exceeding 4.5 grams every 6 hours are uncommon and may depend on specific clinical scenarios and prescriber judgment. ## Pediatric Dosing Dosing is based on piperacillin content. Calculations are typically done on a weight-based **piperacillin** equivalent. * **Infants and Children (over 12 months):** 80 to 100 mg piperacillin/kg/day divided every 6 to 8 hours. This is usually administered as 100 mg piperacillin/12.5 mg tazobactam per kg/day. * **Neonates and Infants (under 12 months):** Dosing is less established due to pharmacokinetic differences and potential for kernicterus with high doses in neonates. Consult specific guidelines or use with caution. * **Maximum Dose:** Generally not to exceed the adult maximum dose of 4.5 grams per dose. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No dose adjustment needed. * CrCl 20-40 mL/min: Reduce dose frequency to every 8 hours. * CrCl < 20 mL/min: Reduce dose frequency to every 12 hours. * For doses given every 6 hours, the dose should be reduced. For doses given every 8 hours, the frequency should be increased. * Consider administering the dose PRIOR to initiation of intermittent hemodialysis. * **Hepatic Impairment:** No specific dose adjustment is typically recommended, but monitor closely. ## Contraindications * Known history of severe allergic reaction to piperacillin, tazobactam, other penicillin antibiotics, or beta-lactamase inhibitors. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, constipation, elevated liver enzymes. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (particularly with high doses or renal impairment), interstitial nephritis, hematologic changes (e.g., neutropenia, thrombocytopenia). ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations. * **Warfarin:** Piperacillin may decrease serum concentrations of warfarin, potentially leading to a loss of anticoagulant effect. Monitor INR closely. * **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the action of vecuronium. * **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels. ## Monitoring * Renal function (CrCl) for dose adjustments. * Liver function tests. * Complete blood count (CBC) for hematologic abnormalities. * Signs and symptoms of hypersensitivity reactions. * Signs and symptoms of *Clostridioides difficile*-associated diarrhea. * For patients on concomitant warfarin, monitor INR. ## Clinical Pearls * The duration of therapy should be guided by the severity and type of infection, clinical response, and microbiological data. * Ensure adequate hydration and monitor for signs of fluid overload, especially in patients with heart failure, due to the sodium content of the formulation. * The reconstituted solution should be administered intravenously over at least 30 minutes. * In patients with cystic fibrosis, higher doses may be required. *** *This information is intended for healthcare professionals and should not replace clinical judgment. Always refer to the most current prescribing information and institutional protocols for definitive guidance.*